A new butyrophenone in the treatment of chronic schizophrenia

Abstract

Methods Ten drug-resistant male patients, meeting requirements previously described (SIMPSON et al. 1964) were chosen for this study. These chronic schizophrenic patients ranged in age from 27 to 56, averaging 43 years. Length of hospitalization was 8 to 31 years, approximately a 22-year average. The patients were under observation for 16 weeks: 2 weeks of baseline studies, 10 weeks of drug t reatment , and a 4-week withdrawal period. Response was evaluated every 2 weeks by a psychiatrist according to the Inpat ien t Multidimensional Psychiatric Seale (IMPS) (LOR~ et al. 1962) and a Global Rat ing (GI~). In addition, the following ratings were used at weekly intervals : a modified Malamud-Sands nurses rating scale ( T u ~ 1962), a neurologie rating scale of extrapyramidal system disturbance (SIMrsoN et al. 1964a) and a psychiatric evaluation. This lat ter is the weekly clinical assessment of the senior author as to the pat ients ' condition following a meeting with the nurses, aides, recreational and O.T. assistants, a t which the pat ient is discussed and inter-

DOI: 10.1007/BF00405019

Cite this paper

@article{B1965ANB, title={A new butyrophenone in the treatment of chronic schizophrenia}, author={Ch. B. George M. Simpson M. B. and Esther Kunz and T. P. S. Watts}, journal={Psychopharmacologia}, year={1965}, volume={8}, pages={223-226} }